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INTRODUCTION
Homocystinuria (McKusick 236200) due to cysta-
thionine β-synthase (CBS, EC 4.2.1.22) deficiency
is an inborn error in the trans-sulfuration pathway
by which methionine is converted to cysteine. CBS
deficiency results in the accumulation of homo-
cysteine and methionine, and a decreased formation
of cystathionine and cysteine. Untreated patients are
characterized by multisystemic clinical symptoms,
such as dislocated optic lenses, mental retardation,
skeletal abnormalities, and vascular disease with
severe thromboembolic complications (1).
Patients with CBS deficiency usually show elevated
concentrations of both homocystine and methionine
in the blood and urine, even in the neonatal period,
consequently, the blood level of methionine is routinely
measured in neonatal mass screenings for CBS
deficiency worldwide (2). We previously reported
two homocystinuric siblings who showed different
levels of methionine in their blood during the neo-
natal period ; one of them was missed by a mass
screening due to a low level of methionine in the
blood (3). Naughten et al . (1998) pointed out four
possible reasons why a patient with homocystinuria
could be missed in a neonatal mass screening ; i.e.,
early hospital discharge, low protein intake (espe-
cially if breast fed), a high blood methionine cut-off
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concentration and pyridoxine responsiveness. Our
patient who was missed by mass screening did not
show any of these conditions.
Therefore, in this study, we analyzed the CBS
gene in these siblings at the molecular level to
confirm the cause of their different levels of
methionine in the neonatal period.
MATERIAL AND METHODS
Patients :
Clinical and biochemical findings for the patients
have been reported previously (3, 4). In summary,
case 1, a 14-year-old boy, was born without any
complications to Japanese parents who were not
consanguineous. Neonatal mass screening performed
at 5 days after birth when the protein intake was
about 2.5 g/kg with normal milk formula showed
hypermethioninemia, but he was not diagnosed as
having homocystinuria until 3 months of age because
urinary homocystine was not detected. When he
reached 3 months of age, urinary homocystine was
detectable and markedly reduced CBS activity in
cultured skin fibroblasts was identified. Since the
boy did not respond to the oral administration of
pyridoxine, he was treated with a low-methionine
diet and betaine. His physical and psychomotor de-
velopment was normal. Case 2 (the younger sister
of case 1), a 12-year-old girl, was delivered after 41
weeks of gestation without any complications and
weighed 3,352 g at birth. She was fed a normal milk
formula and her protein intake was about 2.5 g/kg at
a neonatal mass screening performed also at 5 days
after birth. Her blood concentration of methionine
was below the cut-off value (67 µmol/L) in a neona-
tal mass screening. Her physical development was
normal, but her mental development, especially her
speech development, was slightly retarded. At 21/2
years, she was found to have hypermethioninemia,
hyperhomocystinemia and homocystinuria. Cysta-
thionine synthase activity in cultured skin fibro-
blasts was undetectable. Oral administration of pyri-
doxine did not decrease the level of homocystine in
the urine and blood. She was then treated with a
low-methionine diet, which kept the level of blood
methionine below 67 µmol/L and total homocyst(e)ine
below 30 µmol/L. Subsequently, each value gradu-
ally rose and betaine was supplemented at 3 years
of age. Her retardation has since improved, and her
IQ score was 91 at 12 years of age.
RNA, DNA and cDNA Preparation :
Total RNA was isolated from cultured skin
fibroblasts from patients and normal control sub-
jects by the guanidinium thiocyanate method (5).
To confirm the detected mutations in family mem-
bers, genomic DNA was isolated from peripheral
mononuclear cells by the proteinase K method, as
described elsewhere (6). Single-strand cDNA was
synthesized from total RNA using a cDNA synthesis
kit (GIBCO-BRL Inc).
Amplification of cDNA, subcloning and sequencing :
The full-length cDNA for CBS was amplified by the
polymerase chain reaction (PCR) using the sense
primer (nt- 31 to-12 ; 5’-GAACTGTCAGCACCATCT
GT-3’) and the antisense primer (nt 1674 to 1655 ;
5’-CGCCCAGCGCTCCGGACTTC-3’). Thirty five
cycles of PCR were performed according to the
following program : denaturation at 94℃ for 1 min,
annealing at 57℃ for 2 min and extension at 72℃
for 3 min. Amplified full-length cDNA of CBS was
subcloned into the vector pCR2.1 using a TA cloning
kit (Invitrogen). Eight independent clones from
case 1 and six clones from case 2 were sequenced
in both directions by the dideoxy chain termination
method using the Sequenase kit (United States
Biochemical) and [35S] dATP as the labeled deoxy-
ribonucleotide.
Detection of mutations in genomic DNA :
To confirm the mutations in genomic DNA, part
of exon 3, around the site of the A194G mutation,
and part of exon 5, around the site of G346A, were
amplified from genomic DNA using primer set A
(tccttgctttgccaggTCCCAGC and atcaaaagcaggactta
CGGGGC) and mismatch primer set B (TGGCCA
AGTGTGAGTTCTTCAACGCCTGC and GATAAT
CGTGTCCCCGGGCTTCAGCGTC), which creates
a Pst I site in PCR products, respectively. After
PCR amplification, PCR products were digested
with Mae III or Pst I, respectively, and analyzed
with 4% NuSieve agarose gel electrophoresis.
Expression of CBS protein in E. coli :
The cDNA encompassing the entire coding region
of normal CBS cDNA was amplified by PCR and
inserted into a pCR2.1 vector. After confirming the
cDNA sequencing, a pCR2.1 vector containing nor-
mal CBS cDNA was digested with Eco RI and a CBS
cDNA fragment was subcloned into the prokaryotic
expression vector pKK223-3 (Pharmacia), and the
direction of the cDNA was confirmed by digestion
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with Pst I (pKK-CBS). To construct the expression
vector of mutant CBS, segments of the patients’
CBS cDNA which contained the individual mutations
were amplified by PCR and replaced by the cor-
responding segment of normal CBS cDNA in the
pKK-CBS plasmid (pKK-CBS-A 194G and pKK-CBS-
G346A). All of the mutant CBS constructs were
confirmed by sequencing. The E. coli strain JM105
was transformed with pKK-CBS, pKK-CBS-A194G
or pKK-CBS-G346A and cultured in 100 ml of the
culture medium at 37℃ overnight. The expression of
CBS protein was induced by adding 1 mM isopropyl
β-D-thiogalactoside (IPTG), and after incubation
at 37℃ for 5 hours, the cells were harvested by
centrifugation. Cells were disrupted by sonication
and centrifuged at 10,000 g for 30 min at 4℃. The
CBS enzyme activity in the supernatant was mea-
sured by the method of Fleisher et al . (7) modified
according to Kozich and Kraus (8).
RESULTS
Detection of mutation :
In case 1, four of eight sequenced clones had the
A-to-G transition at nucleotide 194 (A194G), which
changed an encoded histidine to arginine at codon
65 (H65R) (Fig1A). In case 2, four of six sequenced
clones had the same A194G mutation. These clones
had no other muation. The remaining clones from
cases 1 and 2 had only the G-to-A transition at
nucleotide 346 (G346A), which changed an encoded
glycine to arginine at codon 116 (G116R) (Fig 1 B).
The mutation A194G created a new Mae III site,
and so a 250-bp genomic DNA fragment around
this mutation was amplified by PCR and digested
with Mae III to confirm this mutation in genomic
DNA from patients and their parents. After digestion
with Mae III, a normal control and the father had
only a 250-bp DNA fragment. On the other hand,
these siblings and their mother had three DNA
fragments : 250 bp, 217 bp and 33 bp (Fig 2 A). The
mutation G346A created no new restriction enzyme
sites, and so a 112-bp DNA fragment around this
mutation was amplified using a mismatch primer,
which created a Pst I site in the mutant gene. After
Pst I digestion, a normal control and the mother
had only 112-bp fragments, while the patients and
their father had three fragments : 112 bp, 83 bp and
29 bp (Fig 2 B). These results indicated that these
siblings were compound heterozygotes for these
mutations and their mother and father were hetero-
zygous for A194G and G346A, respectively.
Fig.1. Sequence analysis of CBS cDNA obtained from a normal control and two siblings with CBS deficiency. (A) Four of eight
sequenced clones from case 1 and four of six sequenced clones from case 2 showed an A-to-G transition at nucleotide 194 (A194G),
resulting in a predicted histidine-to-arginine substitution at amino acid 65 (H65R). (B) Four of eight sequenced clones from case 1 and
two of six sequenced clones from case 2 showed a G-to-A transition at nucleotide 346 (G346A), resulting in a predicted glycine-to-arginine
substitution at amino acid 116 (G116R)
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Enzyme activities of the wild-type and mutant CBS
in E. coli :
The wild-type and mutant CBS protein were
expressed by transforming the E. coli strain JM105
with pKK223-3, pKK-CBS-WT, pKK-CBS-A194G or
pKK-CBS-G346A. After the induction of CBS protein
with IPTG, the enzyme activity in E. coli cells, con-
taining the wild-type or one of the two mutant CBS
cDNAs, was measured. CBS enzyme activities in E.
coli without plasmid vector and with pKK-233-3
were not detected. The enzyme activity of wild-type
CBS was 7.63 nmol/min/mg of protein, however,
the activities of CBS from cDNAs with the mutations
A194G and G346A could not be detected, similar
to E. coli without CBS cDNA (Table 1).
DISCUSSION
Since the isolation and characterization of the
human CBS cDNA sequence in 1993, studies on the
CBS mutations in patients with homocystinuria in
the USA and Europe have lead to the identification
of about 64 mutations within the CBS gene (9). In
this study, two mutations in the CBS gene, A194G
and G346A, were found in pyridoxine-nonresponsive
homocystinuric siblings who showed different blood
methionine levels during the neonatal period. The
A194G mutation is new while G346A has been
reported previously in European patients (10). Since
CBS proteins from these mutations had no detect-
able enzyme activity by an expression analysis in
E. coli, these mutations were pathogenic in these
patients. The results of a mutation analysis on
genomic DNA from these patients and their parents
indicated that these siblings were compound hetero-
zygotes of maternal A194G and paternal G346A,
and did not have any other mutations.
To begin treatment for homocystinuria as soon
as possible and to prevent patients from developing
clinical symptoms, the mass screening of new-
borns for homocystinuria due to CBS deficiency is
performed in many countries by measuring the
methionine concentration in blood, since blood
methionine concentrations are usually elevated in
patients with CBS deficiency even during the neo-
natal period (2). In Japan, a nationwide newborn
mass screening program was started in 1972 by
analyzing the methionine concentration in dried
blood spots using a semi-quantitative bacterial inhi-
bition assay. We found two Japanese siblings ; one
Fig.2. Detection of mutations in genomic DNA. Lane M, size marker. Lane 1, normal control. Lane 2, father. Lane 3, case 1. Lane 4,
case 2. Lane 5, mother. (A) Detection of A 194 G in the CBS gene. PCR products (250bp), amplified by primer set A, were digested
by Mae III enzyme, which either gives two fragments of 217 bp and 33 bp in the case of the mutated sequence (194 G) or leaves the
product undigested in the case of the wild-type sequence (194 A). (B) Detection of G 346 A in the CBS gene. PCR products (112 bp),
amplified by mismatch primer set B, were digested by Pst I enzyme, which either gives two fragments of 83 bp and 29 bp in the case
of the mutated sequence (346 A) or leaves the product undigested in the case of the wild-type sequence (346 G).
Table 1. CBS Activity in the Sonicated Supernatant of Trans-
formed E. coli Cells
Plasmid CBS Activity
a)
(nmol/min/mg of total protein)
Non-transformed JM105
pKK223-3
pKK-CBS-WT
pKK-CBS-A194G
pKK-CBS-G346A
n.d.
n.d.
7.63
n.d.
n.d.
n.d. : not detectable
a) CBS activities were measured in two or three separate experi-
ments and the mean value is shown.
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was identified by mass screening based on a high
concentration of methionine in the blood and the
other was missed by a mass screening due to a low
level of methionine in blood, and was diagnosed
after presenting clinical symptoms (3). Yap and
Naughten reported four patients who were missed
by newborn screening for CBS deficiency in Ireland
(11) and Naughten et al . (2) suggested four possible
reasons why a patient with homocystinuria could
be missed by a neonatal mass screening : 1) early
hospital discharge, 2) low protein intake, especially
if breast fed, 3) high blood methionine cut-off con-
centration, and 4) pyridoxine responsiveness. How-
ever, there was no difference in these conditions
between our siblings ; i.e., blood collection was per-
formed at 5 days of age, their protein intakes were
2.5 g/kg/day with normal milk formula, they did
not respond to the administration of a high dose of
pyridoxine, and the cut-off methionine concentra-
tion in the screening program was 67 µmol/L (3),
which is the lowest cut-off value in the world (2).
We analyzed the CBS gene in these siblings at the
molecular level because it was possible that their
genotypes were different although they were sib-
lings, and so that they showed different methionine
concentrations in the neonatal period. However,
they had identical genotypes for the CBS gene ; i.e.,
compound heterozygote with A194G and G346A.
CBS is a homotetramer of 63 kd subunits (1). In
tissues of CBS-deficient patients with two mutant
alleles, this enzyme may consist of various hetero-
tetramers of two mutant subunits and/or the for-
mation of heterotetramers of this enzyme may be
disturbed according to the ratio of amounts of the
two mutant subunits. Although the enzyme activ-
ities of a mutated homotetramer of CBS from our
patients expressed in E. coli could not be detected,
heterotetramers of CBS with two mutant subunits
might have some residual enzyme activities. Further-
more, correct CBS folding requires the presence
of heme (9), and the CBS activity depends on the
contribution of several factors, including pyridoxal
5’-phosphate (12), heme biosynthesis (13), and
adenosylmethionine formation (14). Therefore, a
difference in the amount of each type of hetero-
tetramer or in these other factors, which may result
in the disturbance of the heterotetramer formation,
likely affected the CBS activity during the fetal and
neonatal periods in these siblings to cause differ-
ent concentrations of methionine when blood was
collected for screening of CBS deficiency, despite
their identical genotypes.
Blood methionine concentrations are determined
by the activities of enzymes involved in methionine
and homocysteine metabolism, including methionine
adenosyltransferase, CBS, 5-methyltetrahydrofolate-
homocysteine methyltransferase, and betaine-
homocysteine methyltransferase (1). The specific
activities of methionine adenosyltransferase and
betaine-homocysteine methyl-transferase are lower
in fetal liver than in the adult liver, whereas the
activity of 5-methyltetrahydrofolate-homocysteine
methyltransferase is higher in fetal tissue than in
adult tissue (15, 16). This fetal enzyme pattern
should direct a large portion of the available homo-
cysteine to the 5-methyltetrahydrofolate-dependent
methylation cycle rather than to the synthesis of
cystathionin. The failure to detect hypermethioninemia
in some newborn infants with a deficiency of CBS
might be explained by a quantitative difference in
the activities of enzymes involved in the metabolism
of methionine and homocysteine. This suggests that
in our patients, the development of these enzymes,
except CBS, differed during the fetal and neonatal
periods, or the genotypes were different for these
enzymes, which are not pathogenic and result in
different enzyme activities or development patterns,
so that their blood methionine concentrations during
the neonatal period were not the same although
they had identical genotypes for the CBS gene,
which had two pathogenic mutations.
These results indicate that measurement of the
methionine concentration in blood is not adequate for
identifying all patients with pyridoxine-nonresponsive
CBS-deficiency even if they intake enough protein
and are not discharged early, and if the cut-off
value of methionine in neonatal screening is low.
Therefore, to begin treatment as soon as possible
and to prevent patients from developing clinical
symptoms, a CBS gene analysis and/or an assay
of CBS activity should be performed in high-risk
newborns, who have siblings with CBS deficiency,
even if the results of a neonatal screening for CBS
deficiency are normal. In addition, a new, more
sensitive method for the mass screening of CBS
deficiency in neonates, by which all patients with
CBS deficiency can be detected, should be devel-
oped.
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